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degree of specificity with which OP-1 bound to kidney recep-Characterization of receptors for osteogenic protein-1/bone
tors. Scatchard analysis of quantitative binding data indicatedmorphogenetic protein-7 (OP-1/BMP-7) in rat kidneys.
that the OP-1 receptors of kidney contained a single class ofBackground. Osteogenic protein-1/bone morphogenetic pro-
high-affinity binding sites for OP-1 with an association constanttein-7 (OP-1/BMP-7), a member of the transforming growth
(Ka) of 2.26 3 109 mol/L21 and a binding capacity of 1.01 pmolfactor-b superfamily, has been shown to prevent kidney dam-
of OP-1 per mg membrane protein. When analyzed by a ligandage from ischemia/reperfusion injury in rats. The molecular
blot technique, plasma membranes isolated from kidney cortexevents involved in OP-1 action on kidney are not yet understood.
and medulla each showed the presence of a prominent specificMethods. In this study, we evaluated the biodistribution of
band with a relative molecular mass (Mr) of 100 kD. Further125I-labeled OP-1 in rat kidneys. Adult rats received a single
analysis by Western blotting indicated that an antibody raisedintravenous injection of 250 mg 125I-labeled OP-1 per kg body
against BMP type II receptor effectively recognized the 100 kDwt, a dose that was effective in protecting kidneys from ischemic
OP-1 binding component of kidney plasma membranes.injury. Tissue localization, in situ hybridization, and immuno-
Conclusions. We demonstrated, to our knowledge for thestaining with a specific receptor antibody were performed to
first time, the presence of membrane-bound, specific, high-identify OP-1 cellular targets. Also, isolated plasma membranes
affinity OP-1 receptors in rat kidney tissues, which are likelyfrom kidney cortex and medulla regions were analyzed to iden-
to mediate OP-1 actions in the kidney. The major OP-1–bindingtify and characterize receptor structural components that rec-
component of the kidney appears to be a long form of BMPognize OP-1.
type II receptor with a Mr of 100 kD. In vivo and in vitroResults. At 10 and 180 minutes following injection, the rela-
evidence suggests that the cellular targets for OP-1 are convo-tive uptake of 125I-labeled OP-1 was consistently higher in kid-
luted tubule epithelium, glomeruli, and collecting ducts. OP-1ney cortex than in medulla region. Upon autoradiography,
kidney tissue sections revealed that OP-1 bound to the convo- does not share receptor binding properties with other growth
luted tubule epithelium, glomeruli, and collecting ducts. More- factors, including BMP-2 and CDMP-1, suggesting that its
over, in situ hybridization and immunostaining methods have mode of action in kidney appears to be specific.
shown localization of mRNA transcripts and the protein for
BMP receptor type II in the cortex and medulla in similar areas
as 125I-labeled OP-1. Bulk membranes (enriched with plasma
Bone morphogenetic proteins (BMPs) are a family ofmembranes) isolated from the cortex and medulla regions of
multifunctional proteins originally identified as proteinskidney each bound specifically to 125I-OP-1, and the binding of
125I-labeled OP-1 was inhibited by unlabeled OP-1 in a dose- that induce bone and cartilage formation at ectopic extra-
dependent manner. However, platelet-derived growth factor, skeletal sites in vivo [1, 2]. These are glycosylated proteins
transforming growth factor-b, insulin-like growth factor, fibro- and belong to the transforming growth factor-b (TGF-b)
blast growth factors, and other members of BMP family such as
superfamily. BMP-2 and BMP-4 are highly similar to eachBMP-2 and cartilage-derived morphogenetic protein-1/growth
other in structure (92% amino acid sequence identity),and differentiation factor-5 (CDMP-1/GDF-5) failed to inhibit
the binding of 125I-labeled OP-1 to receptors, suggesting a high while they are distantly related to osteogenic protein-1
(OP-1/BMP-7; 58 to 60% amino acid sequence identity).
In vitro, OP-1 stimulates alkaline phosphatase activity1 See Editorial by Kopp, p. 2237
2 Present address: Kuber T. Sampath, Arthrosome, Inc., P.O. Box 6349, and collagen synthesis in osteoblasts, proteoglycan syn-
Holliston, MA 01746 thesis in chondroblasts, chemotaxis of monocytes, and
differentiation of neural cells [3, 4]. Also, OP-1 has im-Key words: transforming growth factor-b superfamily, convoluted tubule
epithelium, glomeruli, receptor binding, ischemia/reperfusion injury. portant roles in the morphogenesis of embryo and in
postnatal life [5, 6]. It is produced in the kidney [5, 7],Received for publication July 14, 1999
induces nephrogenesis, and is required for eye develop-and in revised form May 25, 2000
Accepted for publication May 30, 2000 ment and skeletal patterning [8–10]. More recent studies
have shown that OP-1 is able to prevent kidney damageÓ 2000 by the International Society of Nephrology
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from ischemia/reperfusion injury in rats [11]. The molec- pH 7.4, containing 5 mmol/L MgCl2, 1 mmol/L CaCl2,
and 0.1 mol/L sucrose at a protein concentration of 11.5ular events involved in OP-1’s action on the kidney are
not yet understood. In this study, we evaluated the bio- mg/mL, and they were snap frozen and stored at 2708C
until used in the binding assay.distribution of 125I-labeled OP-1 in the rat kidney and
analyzed kidney bulk membranes to identify and charac-
Specific uptake of 125I-labeled OP-1 by rat kidneyterize the OP-1 receptor structural component(s) that
membrane receptorrecognizes OP-1.
Highly purified soluble OP-1 (25 mg) was radioiodin-
ated to a high specific activity (70 to 76 mCi/mg) with 2
METHODS
mCi of carrier-free Na125I, using a modification of the
Preparation of 125I-labeled OP-1 lactoperoxidase method of Dattatreyamurty, Schneyer
and Reichert [12]. Bulk membranes isolated from ratHighly purified mature OP-1 (15.7 mg) was radioiodin-
ated with 5 mCi of carrier-free Na125I using a modification kidney cortex and medulla were separately incubated
with approximately 300,000 cpm (3 ng) of 125I-labeled OP-1of the lactoperoxidase method of Dattatreyamurty et al
[12]. Gel filtration on a Sephadex G-25 column was used in the absence or presence of excess unlabeled OP-1.
Membrane (receptor)-bound radioligand was separatedto separate radioiodinated OP-1 from free iodide. The
column was eluted with 20 mmol/L sodium acetate buf- from free radioligand by centrifugation at 30,000 3 g for
60 minutes at 48C. The final pellet containing receptor-fer, pH 4.5, containing 0.2% Tween-80 and 0.1% oval-
bumin. Specific activity of the radioiodinated OP-1 prep- bound 125I-labeled OP-1 was counted in an auto-g
counter. Values reflecting specific binding are expressedaration used in this study was 0.237 mCi/mg.
as a percentage of total radioligand added to the mem-
Biodistribution of 125I-labeled OP-1 brane-bound receptor (B/T%).
Sprague-Dawley rats with an average body weight of
Radioligand receptor binding assay400 g received a single intravenous injection of 125I-labeled
OP-1 at a dose level of 250 or 1000 mg/kg body weight. Using bulk membranes of rat kidney cortex as the
source for receptor and 125I-labeled OP-1 as a ligand, weAnimals were sacrificed at 10 or 180 minutes following
injection. One kidney and liver were removed, fixed in developed a sensitive radioligand receptor binding assay.
The assay was carried out as follows: 150 mL of assay buf-4% paraformaldehyde, and postfixed in 70% ethanol.
The other kidney (unfixed) was dissected to separate fer [50 mmol/L HEPES, pH 7.4, containing 10 mmol/L
MgCl2, 1 mmol/L CaCl2, 0.1 mol/L sucrose, and 1% bo-cortex and medulla. The relative uptake of 125I-labeled
OP-1 by tissues was expressed as ng of radiolabeled vine serum albumin (BSA)] or assay buffer containing
increasing concentrations of unlabeled OP-1 (5 ng toOP-1 per gram wet tissue weight. To evaluate tissue
distribution of radioiodinated OP-1, the kidney sections 10.48 mg) was added to assay tubes. Membranes (approx-
imately 200 mg protein in 200 mL of 50 mmol/L HEPESwere coated with Kodak NTB2 emulsion, exposed for
two weeks at 48C, and lightly stained with Gienesa stain buffer, pH 7.4, containing 5 mmol/L MgCl2, 1 mmol/L
CaCl2, and 0.1 mol/L sucrose) and approximately 300,000as previously described [13].
cpm (3 ng/50 mL of assay buffer) of 125I-labeled OP-1
In situ hybridization were added to assay tubes and were incubated for 22
hours while rocking at 48C. To the tubes, 400 mL ofBone morphogenetic protein receptor type II mRNA
distribution was analyzed on kidney sections using spe- HEPES buffer without sucrose were added. The contents
were mixed and centrifuged at 30,000 3 g for 45 minutescific RNA sense and antisense probes (a gift from Peter
ten Dijke) [14], and in situ hybridization was performed at 48C to separate free radioligand from receptor-bound
radioligand. The supernatant was aspirated, and pelletas previously described [5].
was suspended in 0.8 mL HEPES buffer without sucrose.
Preparation of plasma membrane-enriched fractions The tubes were then centrifuged at 30,000 3 g for 45
(bulk membranes) from rat kidney cortex and medulla minutes at 48C. The supernatant was aspirated, and the
radioactivity of the pellet containing receptor-bound ra-Kidneys from normal young rats were dissected to
separate cortex and medulla. The tissues were separately dioligand was counted in an auto-g counter. The results
(B/B0%) are expressed as a percentage of specific bindinghomogenized, and membranes were isolated using a
modification of the procedure described earlier [15]. Al- determined in the absence of unlabeled OP-1. The affin-
ity constant (Ka) was determined from competitive datathough these membranes are enriched with plasma mem-
branes, as revealed by the content of a marker enzyme, by Scatchard analysis using the LIGAND program of
Munson and Rodbard [16].59-nucleotidase, they were not purified further and there-
fore should be considered as bulk membranes. Mem- To evaluate the specificity of OP-1 interaction with the
kidney receptors, we performed a radioligand receptorbranes were suspended in 50 mmol/L HEPES buffer,
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assay. In this assay, kidney cortex bulk membranes were at 48C and further incubated for 20 hours at room tem-
perature in blocking buffer containing 125I-labeled anti-incubated for 20 hours with 300,000 cpm (approximately
3 ng) of 125I-labeled OP-1 in the presence or absence of BMP type II receptor antibody (,5 3 105 cpm/mL). The
blots were washed four times with 50 mmol/L Tris-HClincreasing concentrations of unlabeled OP-1, platelet-
derived growth factor (PDGF), TGF-b, insulin-like growth buffer containing 150 mmol/L NaCl and 0.05% Tween-
20, dried and subjected to autoradiography. The positionfactor (IGF), fibroblast growth factor (FGF), cartilage-
derived morphogenetic protein (CDMP), and BMP-2 of the Mr standards is indicated on the left side of sample
lines. The position of specific bands indicating OP-1 re-(all prepared at Creative BioMolecules) for 20 hours at
48C. Radioligand receptor binding assay was performed ceptor is shown by an arrow (Fig. 7).
essentially as described previously in this article. The
results (B/B0%) are expressed as a percentage of specific RESULTS
binding determined in the absence of unlabeled OP-1
Biodistribution of 125I-labeled OP-1 in rat kidneysor other growth factors.
and liver
Ligand blot analysis of the OP-1 receptor in rat Sprague-Dawley rats were injected intravenously with
kidney bulk membranes 125I-labeled OP-1 at dose levels of 250 mg and 1000 mg/kg
body weight. The corresponding doses of the low specificMembranes isolated from rat kidney cortex or medulla
were treated with sodium dodecyl sulfate (SDS; final activity 125I-labeled OP-1 preparation were 59.26 mCi and
237 mCi/kg body weight, respectively. Animals were sac-concentration 1.6%, wt/vol) in the presence of 14.3%
glycerol, without prior heating, and subjected to SDS- rificed at intervals of 10 minutes and 3 hours following
injections. Blood levels of 125I-labeled OP-1 decreasedpolyacrylamide gel electrophoresis (SDS-PAGE) in 5 to
9% acrylamide gradient gels under nonreducing condi- rapidly over first 15 minutes following injection, and
thereafter, the levels declined slowly. Following OP-1tions according to the procedure of Laemmli [17]. Elec-
trophoresis of samples was carried out at 35 mA constant injection at a low dose, the average OP-1 uptakes by
kidney cortex observed at 10 and 180 minutes were 270current at 48C. Resolved proteins were transblotted onto
polyvinylidene difluoride (PVDF) membranes using a and 80 ng/g tissue, respectively (Fig. 1A). At a higher
OP-1 dose level, the distribution of OP-1 in kidney cortexPharmacia-LKB 2005 Transphor unit at 0.2 A and 48C for
16 hours. The sample lanes were incubated with blocking did not show much of an increase (Fig. 1B). Interestingly,
the relative uptake of OP-1 observed at 10 and 180 min-buffer (3% BSA in 50 mmol/L HEPES, pH 7.4, con-
taining 5 mmol/L MgCl2 and 1 mmol/L CaCl2) overnight utes following intravenous injection was consistently
higher in the kidney cortex than in the medulla (Fig. 1at 48C and were further incubated for 22 hours in HEPES
buffer containing 0.5% BSA, 10 mmol/L MgCl2, 1 mmol/L A, B). Also, a higher distribution of 125I-labeled OP-1
was observed in the liver.CaCl2, and 125I-labeled OP-1 (,8 3 105 cpm/mL) in the
absence or presence of excess unlabeled OP-1. The blots
Cellular localization of 125I-labeled OP-1 and BMPwere rinsed with 50 mmol/L HEPES buffer containing
receptor type II in rat kidney5 mmol/L MgCl2, 1 mmol/L CaCl2, pH 7.4, and were
dried and subjected to autoradiography. The position of Following an intravenous injection of 125I-labeled OP-1,
kidneys were processed further to evaluate the cellularthe Mr standards is indicated on the left side of sample
lines. The position of specific bands indicating OP-1 re- distribution of radioiodinated OP-1. Upon autoradi-
ography, kidney sections revealed that the majority ofceptor is shown by an arrow in Figure 7.
125I-labeled OP-1 was accumulated in glomeruli and adja-
Western blot analysis of OP-1 receptors in rat kidney cent convoluted tubules, while in the medulla, 125I-labeled
bulk membranes OP-1 grains accumulated in the collecting ducts at 10
and 180 minutes following injection (Fig. 2 A–F). In situA rabbit antiserum raised against the N-terminus pep-
tide region (Ser[185]-Asn[202]) in the extracellular do- hybridization and immunostaining experiments demon-
strated that both mRNA transcripts and the protein formain of type II BMP receptor was affinity purified to
isolate immune IgG. The site-directed antibody (50 mg) BMP receptor type II were localized in the cortex and
medulla in similar areas as 125I-labeled OP-1 (Figs. 2 G, Hwas radioiodinated with 1.5 mCi of Na125I (carrier free)
by using the chloramine-T method. As described in and 3 A–C).
the ligand blot analysis, kidney bulk membranes were
Identification of specific receptors for OP-1 in rattreated with SDS and were subjected to SDS-PAGE,
kidney plasma membranesand then sample proteins were transblotted onto PVDF
membranes. The sample lanes were incubated with Membranes were isolated from the cortex and medulla
of rat kidneys and were analyzed for specific binding ofblocking buffer (2.5% BSA in 50 mmol/L Tris-HCl
buffer, pH 7.4, containing 150 mmol/L NaCl) overnight OP-1 by a radioligand receptor binding assay. When sev-
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decreased markedly because of inhibition by unlabeled
OP-1. These results thus provide an initial evidence for
the presence of OP-1 binding sites in kidney membranes.
Moreover, the relative OP-1 binding (per mg tissue pro-
tein) was observed to be higher in the kidney cortex than
in the medulla (Fig. 4).
Affinity and binding capacity of OP-1 receptors in
kidney cortex
Experiments were carried out to understand the char-
acteristics of OP-1 binding to receptors in the kidney
cortex. Initially, uptake of 125I-labeled OP-1 by increasing
amounts of plasma membranes of kidney cortex was
examined. From the OP-1 uptake profile, optimum con-
centrations of ligand and plasma membrane protein were
determined to set up a sensitive radioligand receptor
assay. In this assay, the binding of 125I-labeled OP-1 to
the kidney cortex plasma membranes was inhibited by
unlabeled OP-1 in a dose-dependent manner (Fig. 5A).
From the quantitative competitive binding data, the Ka
and the binding capacity of OP-1 receptors in the kidney
cortex were determined by Scatchard analysis using the
LIGAND program. The results indicated that the OP-1
receptors of kidney cortex plasma membranes contained
a single class of high-affinity binding sites for OP-1
with a Ka of 2.26 3 109 mol/L21 and the binding capacity
of 1.01 pmol of OP-1 per mg membrane protein (Fig.
5B). The calculated binding capacity of receptors per
gram tissue of kidney cortex was 39.7 pmol OP-1.
Specificity of OP-1 binding to kidney cortex
Radioligand receptor assay was carried out to examine
the specificity with which OP-1 binds to kidney cortex
receptors. In these assays, the effects of increasing con-
centrations of unlabeled OP-1, PDGF, TGF-b, IGF, and
FGF on the binding of 125I-labeled OP-1 to receptor-
enriched plasma membranes of kidney cortex were ex-
amined. Unlabeled OP-1 gave a dose-dependent linear
inhibitory response, while other growth factors such as
PDGF, TGF-b, IGF, and FGF failed to inhibit the bind-Fig. 1. Biodistribution of 125I-labeled osteogenic protein-1 (OP-1) in rat
ing of 125I-labeled OP-1 to kidney cortex plasma mem-kidney and liver. Sprague-Dawley rats received a single intravenous injec-
tion of 125I-labeled OP-1 at two different dose levels: (A) 250 mg/k · g · branes (Fig. 6). These results thus suggest that OP-1
body wt; (B) 1000 mg/kg body weight. Animals were sacrificed at 10 or interacts with kidney cortex receptors with a high degree180 minutes following injection. Rats were perfused with saline and dis-
of specificity. Experiments were continued to examinesected to separate cortex from medulla. The relative uptake of 125I-labeled
OP-1 by tissues was expressed as ng of radiolabeled OP-1 per gram whether other members of BMP family affect OP-1 bind-
wet tissue weight. Symbols are: (j) injected dose; (h) kidney cortex;
ing to the kidney cortex. Two purified preparations,( ) kidney medulla; ( ) liver.
BMP-2 and CDMP-1, were tested in a radioligand recep-
tor assay. In this assay, BMP-2 and CDMP-1 failed to
eral batches of membranes isolated from kidney cortex inhibit the binding of 125I-labeled OP-1 to rat kidney
and medulla were separately incubated with 125I-labeled cortex plasma membranes, while unlabeled OP-1 gave a
OP-1 (,3 ng) for 20 hours at 48C, a significant uptake dose-dependent inhibition curve (Fig. 6B). These results
of radioiodinated OP-1 by each batch of membranes was further substantiate that the OP-1 interaction with the
observed. In the presence of excess unlabeled OP-1, the kidney cortex receptor is highly specific and is not shared
by BMP-2 and CDMP-1.binding of radioiodinated OP-1 to membranes, however,
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Fig. 2. Localization of 125I-labeled osteogenic protein-1 (OP-1) and bone morphogenetic protein (BMP) type II receptor mRNA in rat kidney.
Rats received a single intravenous injection of 250 mg/kg body weight and were killed at 10 minutes following injection (A–F ). (A) Hematoxylin
and eosin-stained brightfield image of a kidney midsagittal section (c, cortex; m, medulla). (B) Darkfield image of the same section with 125I-labeled
OP-1 accumulated in the cortex. (C) Enlarged cortex area from A showing glomeruli (arrowheads) and adjacent convoluted tubules. (D) Darkfield
image of C, indicating accumulation of grains in glomeruli (arrows) and adjacent convoluted tubules. (E) Enlarged medulla (m) and S3 zone (s)
from A. (F) Darkfield image of E, indicating accumulation of grains in epithelium of collecting ducts. For in situ hybridization, rat kidney sections
of 5 to 7 mm thick were cut, mounted on silinated slides, and hybridized with a BMP receptor type II probe for 18 hours at 508C in 50% formamide,
as previously described [5]. (G) Toluidine blue-stained brightfield image of a kidney midsagittal section. Abbreviations are: c, cortex; s, S3 zone;
m, medulla. (H) Darkfield image of an adjacent section with mRNA transcript localized in the cortex and medulla in a similar pattern as 125I-labeled
OP-1 (magnification 35 in A, B, G, and H, and 3200 in C–F).
Identification of type II receptors in kidney cross-linking approach is that it allows direct identifica-
plasma membranes tion of active receptor as well as measurement of relative
molecular mass (Mr) of the receptor proper, but not ofA method (the ligand blot technique) was developed
the receptor-ligand complex. As the radiolabeled OP-1and used to identify OP-1 receptor structural compo-
binding to plasma membranes of medulla was relativelynents in plasma membranes of rat kidneys. The advan-
tage of this method over a previously employed covalent lower than that of plasma membranes of cortex, the mem-
Fig. 4. Specific uptake of 125I-labeled OP-1 by rat kidney bulk mem-
brane receptors. Membranes isolated from rat kidney cortex and me-
dulla were incubated with 300,000 cpm (approximately 3 ng) of 125I-labeled
OP-1 in the absence or presence of excess unlabeled OP-1. Radioligand
assay was performed as described in the Methods section. Values reflect-
ing specific binding of 125I-labeled OP-1 are expressed as a percentage
of total radioligand added to the membrane-bound receptor (B/T%).
Each point is the average of triplicate determinations.
branes from medulla were analyzed at a higher protein
concentration (1.6-fold). When both of the membranes
isolated from kidney cortex or medulla were analyzed by
ligand blotting, each showed the presence of a prominent
band. This band, however, disappeared when the sample-
containing blots were incubated with 125I-labeled OP-1 in
the presence of excess unlabeled OP-1, suggesting a high
degree of specificity with which OP-1 bound to this com-
ponent. A calibration plot of relative mobility (Rf) versus
log molecular weights of protein markers was estab-
lished. The Mr of the identified OP-1 binding component,
as determined from the plot, was 100 kD (Fig. 7A).
Recently, Rosenzweig et al cloned the type II receptor
for BMPs and expressed it in COS-1 cells [14]. The re-
combinant type II receptor is much larger than type I
receptors, and it has an Mr of approximately 100 kD.
Since both kidney cortex and medulla appeared to con-
tain an OP-1–binding component with similar Mr, we
further examined the identity of this component by de-
veloping a Western blot method using 125I-labeled anti-
BMP type II receptor antibody. This is a polyclonal anti-
body raised against a synthetic peptide corresponding to
a variable region (Ser185-Asn202) in the extracellular
domain of BMP receptor type II. The radioiodinated
antireceptor antibody effectively recognized the 100 kD
b
Fig. 3. Immunostaining of a rat kidney with a BMP receptor type II
polyclonal antibody. Strong positive staining was observed in convo-
luted tubules and glomeruli (A and B). At higher magnification (C),
BMP receptor type II protein is present in both a glomerulus (G) and
proximal tubules (magnification 325 in A, 3100 in B, and 3400 in C).
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Fig. 5. (A) Effect of increasing concentrations
of unlabeled OP-1 (dose–response curve) on
the uptake of 125I-labeled OP-1 by kidney
membrane-bound receptors. 125I-labeled OP-1
was incubated in the absence or presence of
indicated concentrations of unlabeled OP-1
with kidney membranes (,200 mg protein) for
22 hours in cold (48C). Radioligand receptor
assay was essentially carried out as described
in the Methods section. Values (B/B0%) are
expressed as a percentage of specific binding
determined in the absence of unlabeled OP-1.
Each point is the average of triplicate determi-
nations. (B) Scatchard plot for the binding of
125I-labeled OP-1 to receptors in kidney bulk
membranes. Affinity constant (Ka) was deter-
mined from competitive data by Scatchard
analysis using the LIGAND program of Mun-
son and Rodbard [16].
OP-1 binding component of rat kidney membranes (Fig. no added advantage, as the relative uptake of OP-1 by
the kidney did not substantially increase, suggesting that7B). The observed band, however, disappeared when
the blot was incubated with the radiolabeled antibody the OP-1 binding sites in kidneys have already reached
close to a saturation level at the lower OP-1 dose tested.that was preincubated with the immunizing receptor pep-
tide (data not shown). These results indicate that the Interestingly, tissue autoradiography, in situ hybridiza-
tion, and immunostaining with a site-directed receptoridentified 100 kD component is possibly BMP type II
receptor, which is consistent with the localization of BMP antibody all identified the convoluted tubule epithelium
and glomeruli in the cortex and the collecting ducts ofreceptor type II in the cortex and medulla, as shown by
in situ hybridization and immunostaining methods (Figs. medulla as the cellular targets for OP-1. Previous studies
have shown that the rat kidney is the major source for2 and 3).
OP-1 and that the major site of OP-1 production is the
epithelium of the collecting ducts within the medulla
DISCUSSION
(abstract; Jin et al, 2nd International Conference on Bone
It has been well established that the in vivo efficacy Morphogenetic Proteins, Sacramento, A96, 1997) [20].
of drug candidates depends not only on their activity Taken together, these results suggest that OP-1 might
profiles, but also on their ability to target specific tissues. have both paracrine and autocrine roles in the kidney.
Targeting of a given drug is better understood by its bio- It is pertinent to mention that tissue autoradiography
availability and cellular distribution in tissues. Our study has shown localization of radiolabeled OP-1 in the S3
represents the first examination, to our knowledge, of segment. Moreover, by in situ hybridization, it has been
OP-1 targeting to kidneys after systemic administration found that epithelial cells in the S3 zone synthesize OP-1
in rats. Rats received a single intravenous injection of mRNA. Therefore, it is likely that in case of an ischemic
125I-labeled OP-1 at an effective dose of 250 mg/kg body injury within the S3 zone, exogenously administered
weight or a dose four times higher. Radioactive OP-1 OP-1 binds to cell receptors and protects from necrosis
cleared in a biphasic manner, with a rapid clearance over and infarction, as has been previously demonstrated [11].
the initial 15 minutes and substantially slower clearance A higher uptake of 125I-labeled OP-1 by liver observed
thereafter. We observed an uptake of labeled OP-1 in in this study cannot be attributed to a nonspecific bind-
both the cortex and medulla regions of kidney. The rela- ing, as it has been shown previously that liver has specific
tive uptake of radiolabeled OP-1, however, was higher in BMP receptors [21]. Alternatively, this may reflect an
the cortex. The average OP-1 uptake by kidney cortex indirect binding of OP-1 to the liver. The indirect binding
observed at 10 and 180 minutes was 270 ng and 80 ng/g of OP-1 may be facilitated by a binding protein present
tissue, respectively. These values of OP-1 are not consid- in circulation. Recently, we have shown that a2-macro-
ered to be low, since studies with other growth factors globulin, which is present in high concentrations in blood,
such as TGF-b and activin also showed low tissue distri- is the predominant binding protein for OP-1 (abstract;
bution [18, 19]. It has been shown that OP-1 at these Dattatreyamurty, 2nd International Conference on Bone
concentrations is effective in cell cultures in maintaining Morphogenetic Proteins, Sacramento, A126, 1997). It is
epithelial phenotype of human proximal epithelial cells. important to note that upon activation by protease, a2-
macroglobulin undergoes a conformational change thatIncreasing the total injected dose of OP-1, however, had
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exposes a previously buried domain close to the carboxyl
terminus that is then recognized by a cell surface receptor
system in the liver, which mediates binding and endocy-
tosis of the complex. Recent studies have shown that
this is the mechanism by which TGF-b is targeted to
liver by binding to activated a2-macroglobulin [22]. In
an independent study, we have shown that OP-1 bound
to native as well as activated forms of a2-macroglobulin
with similar affinities (unpublished data). These results
thus could partly explain why exogenously administered
OP-1 accumulated in the liver. Further experiments,
however, are required to address these possibilities.
It is noteworthy that plasma membranes from both
kidney cortex and medulla showed the presence of spe-
cific receptors for OP-1. The relative abundance of OP-1
binding sites in cortex membranes was much higher than
in medulla region. Moreover, Scatchard analysis indi-
cated that the receptors in kidney cortex contained a
single class of high-affinity OP-1 binding sites, with a Ka
of 2.26 3 109 mol/L21. The calculated binding capacity
of receptors per mg membrane protein was 1.01 pmol
OP-1. In a previous study, a closely related growth factor,
TGF-b, and its interaction with the receptors were stud-
ied in the proximal tubules isolated from rabbit renal
cortex [23]. Interestingly, the binding data revealed the
presence of both high- and low-affinity binding sites for
TGF-b in the renal cortex. Our study, however, showed
no evidence of low-affinity OP-1 binding sites in all
batches of kidney cortex plasma membranes tested. It is
important to note that the endogenous levels of TGF-b
and other related growth factors are normally low, and
high-affinity and low-capacity receptors for these factors
are implicated to mediate their actions.
Another noteworthy observation is the high degree
of specificity with which OP-1 interacts with the kidney
receptors. Thus, other growth factors such as PDGF,
TGF-b, IGF, and FGF, even at high concentrations,
failed to inhibit the binding of 125I-labeled OP-1 to kidney
plasma membrane receptors. Similarly, other members
of BMP family such as BMP-2 and CDMP-1 also failed
to affect OP-1’s interaction with kidney receptors. These
results clearly indicate that OP-1 does not share recep-
tor-binding properties with the other growth factors ex-
Fig. 6. Effect of other growth factors and unlabeled BMPs on the amined, and its mode of action in the kidney appears to
binding of 125I-labeled OP-1 to receptor-enriched kidney cortex bulk be specific. It is important to note that BMP-2 andmembranes. Membranes were incubated with 300,000 cpm (,3 ng) of
CDMP-1 show only 60 and 51% homology, respectively,125I-labeled OP-1 in the presence or absence of increasing concentrations
of (A) unlabeled OP-1 (d), PDGF (j), TGF-b (m), and IGF (.), or with the primary sequence of OP-1, suggesting that an
(B) unlabeled OP-1 (d), FGF (j), CDMP (.), and BMP-2 (m) for 20 OP-1 interaction with kidney cortex receptors may in-hours at 48C. Radioligand assay was performed as described in the
volve regions in OP-1 that are not well conserved amongMethods section. Values (B/B0%) are expressed as a percentage of
specific binding determined in the absence of unlabeled OP-1 or other these growth factors.
growth factors. Each point is the average of triplicate determinations. Recently, Miyazono and his associates cloned type I
and type II receptors for BMPs and expressed them
in COS cells [14, 24]. OP-1 was shown to bind to two
recombinant type I receptors, ALK-2 and ALK-6, and
to ALK-3 less efficiently, and these ALK receptors had
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Fig. 7. Ligand blot or Western blot analysis of the OP-1 receptor in rat kidney bulk membranes. Membranes isolated from rat kidney cortex (C)
or medulla (M) were treated with SDS and subjected to SDS-PAGE in 5 to 9% acrylamide gradient gels under nonreducing conditions and without
prior heating of the samples. After electrophoresis, resolved sample proteins were transblotted onto PVDF membranes. The sample-containing
blots were further subjected to either ligand blot or Western blot analysis. (A) Ligand-blotting: The sample lanes were incubated in blocking buffer
overnight at 48C and then for 22 hours at 48C in HEPES buffer containing 0.5% BSA, 10 mmol/L MgCl2, 1 mmol/L CaCl2, and 125I-labeled OP-1
(,8 3 105 cpm/mL) in the absence (I) or presence (II) of excess unlabeled OP-1. The blots were rinsed with 50 mmol/L HEPES buffer containing
5 mmol/L MgCl2, 1 mmol/L CaCl2, pH 7.4, and were dried and subjected to autoradiography. (B) Western blotting: The sample lanes were incubated
in blocking buffer (2.5% BSA in 50 mmol/L Tris-HCl buffer, pH 7.4, containing 150 mmol/L NaCl) overnight at 48C and then for 20 hours at room
temperature in blocking buffer containing 125I-labeled anti-BMP type II receptor antibody (approximately 5 3 105 cpm/mL). The blots were washed
four times with 50 mmol/L Tris-HCl buffer containing 150 mmol/L NaCl and 0.05% Tween-20 and were dried and subjected to autoradiography.
The position of the Mr standards are indicated on the left side of sample lines. The position of specific band indicating OP-1 receptor is shown
by an arrow.
Mr values in the range of 50 to 58 kD. On the other tal membranous nephropathy, injury to glomerular epi-
thelial cells is associated with an up-regulation of thehand, the recombinant type II receptor is much larger,
and it has two forms, a truncated form with no C-termi- TGF-b2 and TGF-b3 isoforms, and an increase in TGF-b
type I and type II receptor expression. Studies by Flyv-nus extension [25] and a long form with an Mr of approxi-
mately 100 kD [14]. The type II receptor can effectively bjerg et al have shown that an initial increase in renal size
and function in experimental diabetic kidney is alwaysbind OP-1 on its own, while type I receptors are required
to be coexpressed with type II receptor for efficient bind- preceded by an increase in renal IGF-I, IGF-binding
proteins, and IGF receptor concentrations [26]. Clearly,ing to OP-1. In the present study, when plasma mem-
branes isolated from kidney cortex or medulla were ana- those and our present studies signify the importance of
OP-1, OP-1 receptor, TGF-b, TGF receptors, IGF andlyzed by ligand blotting, each showed the presence of a
prominent band with an Mr of 100 kD. Interestingly, the IGF receptors as major regulators in kidney physiology
and renal repair. Whether OP-1 receptors in renal proxi-size of the OP-1 binding component of rat kidney ap-
pears to match with the Mr of cloned BMP type II recep- mal tubules and glomeruli show similar concentration
changes to regulate tubular cell growth and differentia-tor. Further analysis by Western blot method using a
site-directed receptor antibody identified the 100 kD tion after renal injury remains to be elucidated.
In conclusion, to our knowledge for the first time, wecomponent possibly as a BMP type II receptor. Consis-
tent with this observation, both in situ hybridization and have demonstrated the presence of membrane-bound,
specific, high-affinity OP-1 receptors in rat kidney tissuesimmunostaining methods have shown that mRNA tran-
scripts and the protein for BMP receptor type II are to mediate OP-1 actions. The major OP-1–binding com-
ponent of kidney may be a long form of BMP type IIlocalized in glomeruli and adjacent convoluted tubules
of cortex, and in the collecting ducts of medulla. receptor with an Mr of 100 kD. In vivo evidence suggests
that the cellular target for OP-1 are the convoluted tu-Bone morphogenetic proteins, TGF-b, IGF-I, and
IGF-II are recognized as signaling molecules that control bule epithelium and the glomeruli in the cortex, and the
collecting ducts in the medulla region. Moreover, in situgrowth and differentiation during embryogenesis. Re-
cently, it has been shown that OP-1 is capable of pro- hybridization and immunostaining methods have shown
localization of mRNA transcripts and the protein fortecting the kidney against acute renal failure in postnatal
life [11]. Garcia-Ocana, Penaranda, and Esbrit have shown BMP receptor type II in similar areas of cortex and
medulla.that hypertrophy of the proximal tubule is associated
with an increased production of both TGF-b as well as Osteogenic protein-1 does not share receptor-binding
properties with other growth factors, including BMP-2TGF-b receptors [23]. On the other hand, in experimen-
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